PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial , SHIELD I I PETAH TIKVA, Israel , Feb. 16, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical